PDF(Pubmed)
Abstract：
BACKGROUND: COVID-19 demonstrated the possibility of neurological complications such as loss of sense of smell and taste, together with respiratory problems. Respiratory training and rehabilitation of neurological sequelae are essential to improve respiratory function and thus quality of life, and the aim of this study is to evaluate the efficacy of a pulmonary and neurological rehabilitation program.
OBJECTIVE: To apply a treatment to reduce dyspnea, increase exertional capacity, increase vital capacity and respiratory muscle strength, together with an increase in olfactory and gustatory sensitivity in post-SARS-CoV-2 patients.
METHODS: A randomised controlled experimental study was conducted in 220 patients with a medical diagnosis of COVID-19 and more than 5 months of evolution, dyspnoea or perceived fatigue, including olfactory and gustatory perception problems, of whom 200 patients completed the study. 100 patients were randomly assigned to the intervention group, consisting of an inspiratory training treatment plan (Powerbreathe Plus®) combined with aerobic exercise and olfactory gustatory treatment for 31 days, and 100 patients to the control group, for 31 days without any type of therapy.
RESULTS: The study was conducted in post-Covid-19 patients for 5 months. Two hundred patients were divided into an intervention group (n = 100) and a control group (n = 100). The comparison between the groups showed significant differences in spirometric variables; forced vital capacity (p < .001; Eta2 (0.439); Mean: 0,6135), the ratio between both FEV1/FVC (p < 0.01; Eta2 (0.728); Mean:9,313), peak inspiratory pressure (p < 0.01; Eta2 (0.906); Mean:4,526); changes were observed in dyspnoea measured with the modified Borg scale (p < 0.01; Eta2 (0.811); Mean:1,481) and the modified Medical Research Council scale (p < 0.01; Eta2 (0.881); Mean: 0.777); finally, changes were found in neurological variables, in the questions of the Singapore Smell and Taste Questionnaire, How was your sense of smell after treatment? (p < 0.01; Eta2 (0.813); Mean: 1,721) and How is your sense of taste after treatment? (p < 0.01; Eta2 (0.898); Mean: 1,088).
CONCLUSIONS: The implementation of a respiratory rehabilitation treatment plan with the Powerbreathe Plus® device, aerobic exercise and neurorehabilitation with olfactory and gustatory training, is a therapeutic option against respiratory and neurological sequelae in patients who have suffered such sequelae due to the SARS-CoV-2 virus. Clinicaltrials.gov: NCT05195099. First posted 18/01/2022; Last Update Posted 29/06/2022.
OBJECTIVE: To apply a treatment to reduce dyspnea, increase exertional capacity, increase vital capacity and respiratory muscle strength, together with an increase in olfactory and gustatory sensitivity in post-SARS-CoV-2 patients.
METHODS: A randomised controlled experimental study was conducted in 220 patients with a medical diagnosis of COVID-19 and more than 5 months of evolution, dyspnoea or perceived fatigue, including olfactory and gustatory perception problems, of whom 200 patients completed the study. 100 patients were randomly assigned to the intervention group, consisting of an inspiratory training treatment plan (Powerbreathe Plus®) combined with aerobic exercise and olfactory gustatory treatment for 31 days, and 100 patients to the control group, for 31 days without any type of therapy.
RESULTS: The study was conducted in post-Covid-19 patients for 5 months. Two hundred patients were divided into an intervention group (n = 100) and a control group (n = 100). The comparison between the groups showed significant differences in spirometric variables; forced vital capacity (p < .001; Eta2 (0.439); Mean: 0,6135), the ratio between both FEV1/FVC (p < 0.01; Eta2 (0.728); Mean:9,313), peak inspiratory pressure (p < 0.01; Eta2 (0.906); Mean:4,526); changes were observed in dyspnoea measured with the modified Borg scale (p < 0.01; Eta2 (0.811); Mean:1,481) and the modified Medical Research Council scale (p < 0.01; Eta2 (0.881); Mean: 0.777); finally, changes were found in neurological variables, in the questions of the Singapore Smell and Taste Questionnaire, How was your sense of smell after treatment? (p < 0.01; Eta2 (0.813); Mean: 1,721) and How is your sense of taste after treatment? (p < 0.01; Eta2 (0.898); Mean: 1,088).
CONCLUSIONS: The implementation of a respiratory rehabilitation treatment plan with the Powerbreathe Plus® device, aerobic exercise and neurorehabilitation with olfactory and gustatory training, is a therapeutic option against respiratory and neurological sequelae in patients who have suffered such sequelae due to the SARS-CoV-2 virus. Clinicaltrials.gov: NCT05195099. First posted 18/01/2022; Last Update Posted 29/06/2022.
摘要：
背景：COVID-19显示了神经系统并发症的可能性，例如嗅觉和味觉丧失，以及呼吸系统问题。呼吸训练和神经系统后遗症的康复对于改善呼吸功能和生活质量至关重要，这项研究的目的是评估肺和神经康复计划的疗效。
目的：应用治疗以减少呼吸困难，增加消耗能力，增加肺活量和呼吸肌力量，SARS-CoV-2后患者的嗅觉和味觉敏感性增加。
方法：对220例诊断为COVID-19且进化超过5个月的患者进行了一项随机对照实验研究，呼吸困难或感觉疲劳，包括嗅觉和味觉问题，其中200名患者完成了研究。将100例患者随机分配到干预组,包括吸气训练治疗计划（PowerbreastPlus®）结合有氧运动和嗅觉味觉治疗31天，对照组为100名患者，31天没有任何类型的治疗。
结果：该研究在新冠肺炎后患者中进行了5个月。将200例患者分为干预组（n=100）和对照组（n=100）。两组之间的比较显示肺活量测定变量的显着差异；强迫肺活量（p<.001;Eta2（0.439）;平均值：0,6135），FEV1/FVC之间的比率(p<0.01；Eta2(0.728)；平均值：9,313)，峰值吸气压力（p<0.01；Eta2（0.906）；平均值：4,526）；用改良的Borg量表（p<0.01；Eta2（0.811）；平均值：1,481）和改良的医学研究委员会量表（p<0.01；Eta2（0.881）；平均值：0.777）；最后，在神经变量中发现了变化，在新加坡气味和味道问卷的问题中，治疗后的嗅觉如何？（p<0.01;Eta2（0.813）;平均值：1,721）和治疗后的味觉如何？（p<0.01;Eta2（0.898）;平均值：1,088）。
结论：使用PowerbrokePlus®设备实施呼吸康复治疗计划，有氧运动和神经康复与嗅觉和味觉训练，是针对因SARS-CoV-2病毒而遭受此类后遗症的患者的呼吸和神经系统后遗症的治疗选择。Clinicaltrials.gov:NCT05195099.首次发布于2022年1月18日；最后更新发布于2022年6月29日。
目的：应用治疗以减少呼吸困难，增加消耗能力，增加肺活量和呼吸肌力量，SARS-CoV-2后患者的嗅觉和味觉敏感性增加。
方法：对220例诊断为COVID-19且进化超过5个月的患者进行了一项随机对照实验研究，呼吸困难或感觉疲劳，包括嗅觉和味觉问题，其中200名患者完成了研究。将100例患者随机分配到干预组,包括吸气训练治疗计划（PowerbreastPlus®）结合有氧运动和嗅觉味觉治疗31天，对照组为100名患者，31天没有任何类型的治疗。
结果：该研究在新冠肺炎后患者中进行了5个月。将200例患者分为干预组（n=100）和对照组（n=100）。两组之间的比较显示肺活量测定变量的显着差异；强迫肺活量（p<.001;Eta2（0.439）;平均值：0,6135），FEV1/FVC之间的比率(p<0.01；Eta2(0.728)；平均值：9,313)，峰值吸气压力（p<0.01；Eta2（0.906）；平均值：4,526）；用改良的Borg量表（p<0.01；Eta2（0.811）；平均值：1,481）和改良的医学研究委员会量表（p<0.01；Eta2（0.881）；平均值：0.777）；最后，在神经变量中发现了变化，在新加坡气味和味道问卷的问题中，治疗后的嗅觉如何？（p<0.01;Eta2（0.813）;平均值：1,721）和治疗后的味觉如何？（p<0.01;Eta2（0.898）;平均值：1,088）。
结论：使用PowerbrokePlus®设备实施呼吸康复治疗计划，有氧运动和神经康复与嗅觉和味觉训练，是针对因SARS-CoV-2病毒而遭受此类后遗症的患者的呼吸和神经系统后遗症的治疗选择。Clinicaltrials.gov:NCT05195099.首次发布于2022年1月18日；最后更新发布于2022年6月29日。
